Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.
about
Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemiaEpigenetic regulators and their impact on therapy in acute myeloid leukemiaGenomics-based Approach and Prognostic Stratification Significance of Gene Mutations in Intermediate-risk Acute Myeloid LeukemiaMolecular prognostic factors in cytogenetically normal acute myeloid leukemiaCIViC databaseAcute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Prognostic relevance of Wilms tumor 1 (WT1) gene Exon 7 mutations in-patient with cytogenetically normal acute myeloid leukemiaSingle nucleotide polymorphisms in the Wilms' tumour gene 1 in clear cell renal cell carcinomaFLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotypeMolecular diagnostics in acute leukemias.DNA repair gene polymorphisms and clinical outcome of patients with primary small cell carcinoma of the esophagus.Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations.Next-generation sequencing reveals clinically actionable molecular markers in myeloid sarcomaBone marrow transplantation and acute myeloid leukemia: Brazilian guidelines.Overexpression of ATP1B1 predicts an adverse prognosis in cytogenetically normal acute myeloid leukemiaPotential of whole-genome sequencing for determining risk and personalizing therapy: focus on AMLHomology modeling and molecular dynamics studies of Wilms' tumor gene 1 frameshift mutations in exon 7.Peptide vaccines for patients with acute myeloid leukemia.Molecular diagnosis of acute myeloid leukemia.Older patients with acute myeloid leukemia.Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.Molecular markers in acute myeloid leukaemia.Acute myeloid leukemia with normal cytogenetics.Prognostic factors for acute myeloid leukaemia in adults--biological significance and clinical use.WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy.Diagnosing and following adult patients with acute myeloid leukaemia in the genomic age.Transcription factor mutations in myelodysplastic/myeloproliferative neoplasmsImprinted genes in myeloid lineage commitment in normal and malignant hematopoiesis.A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia.Telomerase reverse transcriptase (TERT) A1062T mutation as a prognostic factor in Egyptian patients with acute myeloid leukemia (AML).Prevalence and Prognostic Value of IDH1 R132 Mutation in Newly Diagnosed AML Egyptian Patients with Normal Karyotype.Association between DCK 35708 T>C variation and clinical outcomes of acute myeloid leukemia in South Chinese patients.Prognostic impact of Wilms tumor gene mutations in Egyptian patients with acute myeloid leukemia with normal karyotype.A 4-gene expression score associated with high levels of Wilms Tumor-1 (WT1) expression is an adverse prognostic factor in acute myeloid leukaemia.The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia.Acute myeloid leukemia with del(9q) is characterized by frequent mutations of NPM1, DNMT3A, WT1 and low expression of TLE4.Wilms tumor 1 gene mutations in patients with cytogenetically normal acute myeloid leukemia.
P2860
Q26744111-E6983852-2526-4FAC-8764-18B21BC75766Q26765402-16A1C756-BAAF-43BD-8202-2F8E3D8B6FCBQ26796514-415346F5-BB1A-4EED-B39C-7D16C15F37A9Q26998811-A9026D46-19E4-4A4D-9F0A-B266AA56F47BQ27612411-3796DE92-8F5E-4A67-99FA-9C7948FE9EC4Q27851694-1AD2F6B0-2772-435F-9E67-D3F9CC7DA627Q34052581-DA0C1F49-16A2-496C-914F-8CBD005426AFQ34052614-3AB9806D-B80E-4BC7-AE78-403BA83C145AQ34569014-E42B656A-A38D-45DD-B2FE-4CF1D0CF12F2Q34618828-CAE22E74-E245-42D6-9BCE-F1B969937CC9Q34890418-7693E543-2F3B-42F0-A40A-567C552BE997Q35007333-C7271D2F-ED64-4E54-87CD-C54AE0F63F37Q35221075-AA87D1AA-CD58-4B18-9087-058E13FC7672Q35265946-EB296A7C-8FE4-4ABA-8221-1DDF6946FF0FQ35849281-8E3DF309-5A9B-4A38-AAAD-184222E43941Q36074241-3AAFC3DB-58E6-4F59-B321-C8D143810316Q36753274-16EB83A4-B1B3-4473-A08B-2768748F750DQ36771874-4225A857-8CF1-4B32-9E19-855A113534F2Q36797201-4DE9314C-CB3F-4A85-BDB3-C013ED898D00Q37567685-AC62D3A6-C5AF-46BC-AD1E-AE090611AA0DQ37608316-444BB9C0-A8E4-4D0F-BE84-DC79CA1C068AQ37809866-EC7C35EC-11DC-4F7E-A0DB-F2516535965FQ37810969-ACEF3DB3-D331-4D16-927C-31E712794BD7Q37934964-BFAB9F4B-077A-4D3B-BB4D-19C81BCF31EBQ38026007-58E5CDDC-3568-4B26-AD45-8935F8677740Q38027047-4593A273-077A-4379-ABC0-14934DCA6D47Q38183943-F874623C-DD32-45FD-BEB8-C15F5C0372CBQ38187457-B2182E75-DAD2-4A79-AEA1-CA7FDE4DF302Q38240563-7DD9148E-C79D-4D4E-87A8-1F90241EDF2BQ38344558-95DA9567-9F1B-47BA-91CB-6A2BAAC48393Q38363814-AB3810EE-EC05-45B0-8F58-96D24E782832Q38661750-9F87549C-A620-4A6D-90B1-D00F2387DBCCQ38879091-97C81255-9E5A-4724-9845-3ADB22E9E509Q38963204-50226625-BFC6-44DE-A31D-2F03E725CBC5Q39467256-B1443E6F-09A0-43D0-B056-65C410F53A52Q39631733-BEE2AC28-729E-4055-9814-8F8624877DC8Q40226406-249BB1A3-7CA5-4015-89C0-95D1EA11E3F9Q40279088-74F01B03-6B04-487F-8BA4-51A6D6AC0F96Q40519126-6E856A23-3B10-48C4-B4EF-B9F7913EB6EDQ42191008-3C1FB272-6A31-47AD-AC45-5D7EBC35D108
P2860
Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Prognostic impact of WT1 mutat ...... rman-Austrian AML Study Group.
@ast
Prognostic impact of WT1 mutat ...... rman-Austrian AML Study Group.
@en
Prognostic impact of WT1 mutat ...... rman-Austrian AML Study Group.
@nl
type
label
Prognostic impact of WT1 mutat ...... rman-Austrian AML Study Group.
@ast
Prognostic impact of WT1 mutat ...... rman-Austrian AML Study Group.
@en
Prognostic impact of WT1 mutat ...... rman-Austrian AML Study Group.
@nl
prefLabel
Prognostic impact of WT1 mutat ...... rman-Austrian AML Study Group.
@ast
Prognostic impact of WT1 mutat ...... rman-Austrian AML Study Group.
@en
Prognostic impact of WT1 mutat ...... rman-Austrian AML Study Group.
@nl
P2093
P50
P1433
P1476
Prognostic impact of WT1 mutat ...... rman-Austrian AML Study Group.
@en
P2093
Andrea Corbacioglu
Annegret Becker
Arnold Ganser
Jürgen Krauter
Lars Bullinger
Richard Friedrich Schlenk
Simone Moschny
Verena Ingeborg Gaidzik
P304
P356
10.1182/BLOOD-2008-10-183392
P407
P577
2009-05-07T00:00:00Z